Babu, Venkata Pradeep KTalwar, VineetRaina, ShubhraGoel, VarunDash, Prasanta KBajaj, RajatSharma, ManishMedisetty, PavaniRam, DharmaAgrawal, ChaturbhujDesiraju, KoundinyaDoval, Dinesh C2020-01-022020-01-022018-07Babu Venkata Pradeep K, Talwar Vineet, Raina Shubhra, Goel Varun, Dash Prasanta K, Bajaj Rajat, Sharma Manish, Medisetty Pavani, Ram Dharma, Agrawal Chaturbhuj, Desiraju Koundinya, Doval Dinesh C. Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre. Indian Journal of Cancer. 2018 Jul; 55(3): 222-2250019-509Xhttp://imsear.searo.who.int/handle/123456789/190355BACKGROUND: Gemcitabine plus cisplatin has been established as a standard chemotherapy regimen for advanced biliary tract cancers (BTCs) based on the phase III UK ABC-02 study, which included all types of biliary cancers. There is very limited data regarding the effectiveness of known chemotherapeutic regimens especially in IHCC. METHODS: Records of 63 patients diagnosis of IHCC who received Gemcitabine and Carboplatin (G-C Regimen) chemotherapy as a first line were retrospectively reviewed. The primary aim of this study was to assess the response rate of gemcitabine carboplatin-based chemotherapy as a first line therapy in advanced intrahepatic cholangiocarcinoma (IHCC). The secondary objectives were to assess toxicity, progression free survival and overall survival. RESULTS: There were 38 men and 25 women in our study with a median age of 56.75 years (range 31–78 years). Of the 38+25= 63 patients, 21 patients (33.8%) progressed, 5 patients (8.06%) had complete response, 25 patients (40.3%) had partial response, 12 patients (19.3%) had stable disease. Overall response rate was 48.36% and tumor control rate was 67.6%. Progression free survival was 5.3 months and overall survival of 10.3 months was seen. The most common grade 3–4 toxicities were anemia, neutropenia, and thrombocytopenia. Most common nonhematological toxicity was fatigue. CONCLUSION: Gemcitabine in combination with carboplatin has activity against advanced IHCC. Our results are comparable with other gemcitabine carboplatin studies as well as gemcitabine cisplatin-based studies.Journal ArticleIndiaDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IndiaDepartment of Anaesthesia, Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, New Delhi, IndiaDepartment of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IndiaMedical Research Officer, CSIR - Institute of Genomics and Integrative Biology, New Delhi, India